Skip to main content
. 2014 Jun 10;142(3):354–362. doi: 10.1111/imm.12212

Figure 2.

Figure 2

Serum interleukin-15 (IL-15) levels (pg/ml) at baseline and after each rituximab cycle. Discontinued line represents the mean of healthy donors (n = 10). In the group of serIL15+ rheumatoid arthritis patients (I-cycle n = 25, II-cycle n = 17 and III-cycle n = 13) P-values correspond to the comparison of serum IL-15 levels after each rituximab cycle with the baseline (t = 0) by Wilcoxon test for paired samples. Results were expressed as the mean and error bars represent SD.